Abbott Receives FDA Approval For CREON (Pancrelipase) Infant-Specific Dosage For Patients With Exocrine Pancreatic Insufficiency Due To Cystic Fibrosis
Abbott announced that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).